Share capital increase registered
(Oslo, Norway, 11 October 2016) Reference is made to the stock exchange announcement dated 4 October 2016 concerning the final result of the rights issue (the “Rights Issue”) of 525,000,000 new shares in Bionor Pharma ASA (“Bionor” or the “Company”, ticker “BIONOR”) at a subscription price of NOK 0.10.
STOCK EXCHANGE ANNOUNCEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES
The share capital increase pertaining to the Rights Issue has now been registered in the Norwegian Register of Business Enterprises.
Bionor's new share capital is NOK 138,566,909.70 divided into 1,385,669,097 shares, each with a nominal value of NOK 0.10 and each giving one vote at the Company's general meeting.
The new shares will be delivered to each subscriber’s VPS account on or about 11 October 2016, provided that the respective subscriber has paid for its allocated shares. The new shares issued in the Rights Issue will be tradable on the Oslo Stock Exchange on or about 12 October 2016.
SpareBank 1 Markets AS was sole manager for the Rights Issue.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Unni Hjelmaas, Acting CEO, +47 915 19 651, firstname.lastname@example.org
Jens Krøis, CFO, +45 208 01 668, email@example.com
Link to announcement in pdf